News
CSLLY
18.41
-2.02%
-0.38
Weekly Report: what happened at CSLLY last week (0608-0612)?
Weekly Report · 2d ago
Tencent Music, CSL among global large caps with persistent bearish Quant signals
Seeking Alpha · 06/10 13:19
Ord Minnett Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 06/10 01:05
UBS Reaffirms Their Buy Rating on CSL (CMXHF)
TipRanks · 06/09 00:08
Weekly Report: what happened at CSLLY last week (0601-0605)?
Weekly Report · 06/08 10:09
Ord Minnett Remains a Hold on CSL (CMXHF)
TipRanks · 06/03 06:46
BUZZ-Morningstar maintains fair value for CSL despite underperformance 
Reuters · 06/02 21:33
Weekly Report: what happened at CSLLY last week (0525-0529)?
Weekly Report · 06/01 10:12
BUZZ-Australia's CSL falls on Jefferies downgrade to "hold"
Reuters · 05/29 05:36
Highest and lowest quant-rated healthcare stocks above $10B cap after earnings season
Seeking Alpha · 05/26 14:00
Quant ratings spotlight winners and laggards among large-cap stocks as earnings wind down
Seeking Alpha · 05/26 13:35
CSL (CMXHF) Receives a Buy from Morgan Stanley
TipRanks · 05/26 04:55
Weekly Report: what happened at CSLLY last week (0518-0522)?
Weekly Report · 05/25 10:15
CSL Canada administers first HEMGENIX gene therapy dose to Canadian patient
PUBT · 05/20 10:26
CSL CANADA ANNOUNCES FIRST CANADIAN PATIENT RECEIVES HEMGENIX® (ETRANACOGENE DEZAPARVOVEC) HEMOPHILIA B GENE THERAPY IN ONTARIO, CANADA
Reuters · 05/20 10:00
Weekly Report: what happened at CSLLY last week (0511-0515)?
Weekly Report · 05/18 10:15
Amgen’s Tavneos reportedly linked to 20 deaths in Japan
Seeking Alpha · 05/16 12:23
Citi Sticks to Its Hold Rating for CSL (CMXHF)
TipRanks · 05/14 23:35
Jarden downgrades CSL (CMXHF) to a Hold
TipRanks · 05/12 23:37
Canaccord Genuity downgrades CSL (CMXHF) to a Hold
TipRanks · 05/12 23:36
More
Webull provides a variety of real-time CSLLY stock news. You can receive the latest news about Csl Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CSLLY
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.